Published in BMC Complement Altern Med on April 15, 2010
Gut microbiota and inflammation. Nutrients (2011) 1.60
Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther (2011) 1.52
Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol (2014) 1.17
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol (2014) 1.01
The role of probiotics and prebiotics in inducing gut immunity. Front Immunol (2013) 0.99
New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis (2015) 0.97
A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol Ther (2014) 0.87
Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. World J Gastroenterol (2013) 0.86
Probiotics in inflammatory bowel diseases and associated conditions. Nutrients (2011) 0.85
Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol (2014) 0.85
Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics. Infect Immun (2011) 0.85
Insights from 100 Years of Research with Probiotic E. Coli. Eur J Microbiol Immunol (Bp) (2016) 0.84
Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol (2014) 0.83
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol (2016) 0.83
Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics (2012) 0.81
Probiotics, prebiotics and the gastrointestinal tract in health and disease. Inflammopharmacology (2014) 0.81
Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis. Curr Neuropharmacol (2016) 0.80
Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. Sci Rep (2015) 0.79
Probiotics in the management of ulcerative colitis. Gastroenterol Hepatol (N Y) (2010) 0.79
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol (2016) 0.78
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev (2017) 0.78
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol (2016) 0.78
Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. PLoS One (2015) 0.76
Clinical Evidence for the Microbiome in Inflammatory Diseases. Front Immunol (2017) 0.75
The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System. Front Immunol (2017) 0.75
Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats. Gastroenterol Res Pract (2016) 0.75
Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage. Cancer Biol Ther (2014) 0.75
An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases. Diseases (2015) 0.75
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
Biopsy studies in ulcerative colitis. Br Med J (1956) 4.59
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology (1987) 3.35
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (1997) 3.02
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol (2004) 2.80
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut (2005) 1.72
Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol (2006) 1.53
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol (2005) 1.52
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol (2003) 1.45
Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr (2003) 1.32
Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron (2002) 1.04
Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol (2003) 1.00
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis (1998) 0.96
Ulcerative colitis: diagnosis and management. BMJ (2006) 0.95
Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol (2007) 0.94
Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res (2008) 0.89
Probiotics in the management of colonic disorders. Curr Gastroenterol Rep (2007) 0.87
Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med (2007) 0.85
Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol (2007) 0.85
Probiotics: do they help to control intestinal inflammation? Ann N Y Acad Sci (2006) 0.84
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol (2006) 0.82
Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res (2008) 0.82
[Mutaflor and its medical significance]. Z Klin Med (1951) 0.82
What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J (2006) 0.80
Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci (2007) 0.80
Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment Pharmacol Ther (2006) 0.79
[Probiotics in chronic inflammatory bowel disease]. MMW Fortschr Med (2006) 0.78
[Enema therapy for ulcerative colitis patients]. Nihon Rinsho (2005) 0.77
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol (2004) 2.80
A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol (2002) 1.66
The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr (2007) 1.19
Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol (2003) 1.00
Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J (2008) 0.95
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol (2006) 0.86
The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiology (2005) 0.84
Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis (2013) 0.82
Fatal complications in fistulizing Crohn's disease: brain abscess and squamous cell carcinoma. Int J Colorectal Dis (2012) 0.77
Advanced-stage syphilis unmasking after immunomodulator therapy in a patient with ulcerative colitis. Am J Gastroenterol (2012) 0.75